people on the move
TransCelerate
TransCelerate BioPharma, a non-profit organisation which co-ordinates R&D between drug companies, has appointed an AstraZeneca exec as Chairman of the Board.
Briggs Morrison, Executive VP of Global Medicines Development at AstraZeneca, was welcomed by TransCelerate CEO Dalvir Gill, who said “We are honoured to have our new Chair of the Board join us. His experience, depth of knowledge in this field and clinical insight will further guide the development of our workstream solutions and efforts to address the inefficiencies in the drug development process."
Find more of Outsourcing-Pharma.com’s coverage of TransCelerate here.
TransCelerate also announced Merck & Co. and Novo Nordisk will join the consortium. Other members include AbbVie, AstraZeneca, Boehringer Ingelheim, BSM, Lilly, GSK, J&J, Roche and Sanofi.
